LSPG(SZ:301111)2022-04-25 16:00Revenue and Profitability - The company's revenue for Q1 2022 was ¥60,179,981.94, a decrease of 5.01% compared to ¥63,354,313.80 in the same period last year[3] - Net profit attributable to shareholders increased by 27.41% to ¥13,096,502.82 from ¥10,278,893.07 year-on-year[3] - The company achieved operating revenue of 60.18 million RMB, a year-on-year decrease of 5.01%, primarily due to a reduction in mask product sales revenue by 2.6989 million RMB[17] - The net profit attributable to shareholders increased by 27.41% to 13.6905 million RMB, mainly due to new government subsidies and interest income from cash management of idle funds[17] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 7.2511 million RMB, a year-on-year decrease of 5.22%, primarily due to a decrease in gross profit from mask product sales by 1.0222 million RMB[17] - The total comprehensive income for the first quarter was CNY 13,096,502.82, compared to CNY 10,278,893.07 in the previous period, representing a year-over-year increase of approximately 27.3%[25] Cash Flow and Investments - The net cash flow from operating activities decreased by 30.51% to ¥12,302,965.05, down from ¥17,703,530.84 in the previous year[3] - The cash flow from investing activities showed a drastic decline of 2,532.12%, resulting in a net outflow of ¥352,087,471.95 compared to an inflow of ¥14,476,587.67 last year[10] - Cash inflow from operating activities totaled CNY 81,267,104.24, compared to CNY 76,926,981.86 in the previous period, indicating a growth of approximately 5.5%[28] - Cash outflow from operating activities was CNY 68,964,139.19, up from CNY 59,223,451.02, reflecting an increase of about 16.5%[28] - The net increase in cash and cash equivalents for the period was CNY -351,399,901.25, contrasting with an increase of CNY 32,096,234.17 in the previous period[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥830,291,181.80, reflecting a 0.50% increase from ¥826,198,080.76 at the end of the previous year[3] - The total liabilities decreased to CNY 66,376,482.16 from CNY 75,344,448.75, indicating a reduction of 11.7%[22] - Current assets totaled CNY 715,311,968.70, showing a marginal increase from CNY 708,843,441.99 in the previous period[20] - The company's cash and cash equivalents were CNY 92,602,804.75, compared to CNY 485,348,842.98 in the previous year, indicating a significant decrease[20] Shareholder Information - The total number of common stock shareholders at the end of the reporting period was 31,716[12] - Guangdong Jinou Health Technology Co., Ltd. holds 45.00% of shares, totaling 72 million shares[12] - The top 10 shareholders collectively hold a significant portion of the company's shares, with the largest shareholder holding 45%[12] - The company has a total of 121,968,764 restricted shares at the end of the reporting period[16] - The company plans to release 13,100 shares from strategic placement on December 7, 2022[16] Operational Performance - The company's weighted average return on equity decreased to 1.77% from 3.13% year-on-year, a decline of 1.36%[3] - The company reported a gross profit margin of approximately 13.5% for Q1 2022, compared to 11.5% in the same period last year[23] - The company has maintained stable pharmaceutical sales despite fluctuations in mask product sales[17] - The company is exploring new government subsidies to enhance profitability in future quarters[17] - The company plans to focus on market expansion and new product development in the upcoming quarters[24] Other Income and Expenses - The company reported a significant increase in investment income, rising by 34,151.87% to ¥2,571,236.40 from ¥7,506.85 in the previous year[8] - The company experienced a 248.94% increase in other income, amounting to ¥3,539,913.60 compared to ¥1,014,466.55 in the same period last year[8] - The company reported a 100% decrease in asset disposal income, with no income recorded in the current period compared to a loss of ¥11,209.85 in the previous year[8] - Research and development expenses for Q1 2022 were CNY 2,711,800.92, slightly down from CNY 2,829,323.83 in Q1 2021[24]